Is there a rationale for switching from one anti-tumor necrosis factor agent to another?

Journal of Rheumatology

Volumn 31, Issue 6, 2004, Pages 1021-1022

  Haraoui, Boulos ^a,b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; EDITORIAL; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT FAILURE;

ANTIBODIES; ANTIRHEUMATIC AGENTS; HUMANS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2642543171     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (10)

1. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004;31:1098-102.
2. Brocq O, Plubel Y, Breuil V, et al. Etanercept-infliximab switch in rheumatoid arthritis 14 out of 131 patients treated with anti-TNF alpha [French]. Presse Med 2002;31:1836-9.
3. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab when etanercept has failed or vice versa: data from the STURE registry, showing that switching tumor necrosis factor-alpha blockers can make sense. Ann Rheum Dis 2003;62:1195-8.
4. Ang HTS, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other TNF-alpha antagonists in patients with rheumatoid arthritis. J Rheumatol 2003;30:2315-8.
5. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
7. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9.
8. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
9. Smeets TJ, Kraan MC, van Loon ME, Tak P-P. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-62.
10. Weyand CM, Goronzy JJ. Ectopic germinal center formation in rheumatoid synovitis. Ann NY Acad Sci 2003;987:140-9.